KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Twist Bioscience (TWST) Retained Earnings (2018 - 2025)

Twist Bioscience (TWST) has disclosed Retained Earnings for 6 consecutive years, with -$929.4 million as the latest value for Q1 2023.

  • On a quarterly basis, Retained Earnings fell 29.66% to -$929.4 million in Q1 2023 year-over-year; TTM through Mar 2023 was -$929.4 million, a 29.66% decrease, with the full-year FY2022 number at -$828.4 million, down 35.68% from a year prior.
  • Retained Earnings was -$929.4 million for Q1 2023 at Twist Bioscience, down from -$828.4 million in the prior quarter.
  • In the past five years, Retained Earnings ranged from a high of $363000.0 in Q4 2021 to a low of -$929.4 million in Q1 2023.
  • A 5-year average of -$346.4 million and a median of -$346.3 million in 2019 define the central range for Retained Earnings.
  • Peak YoY movement for Retained Earnings: tumbled 1559108.33% in 2019, then skyrocketed 155.63% in 2021.
  • Twist Bioscience's Retained Earnings stood at -$374.2 million in 2019, then skyrocketed by 100.04% to $142000.0 in 2020, then surged by 155.63% to $363000.0 in 2021, then tumbled by 228313.77% to -$828.4 million in 2022, then decreased by 12.19% to -$929.4 million in 2023.
  • Per Business Quant, the three most recent readings for TWST's Retained Earnings are -$929.4 million (Q1 2023), -$828.4 million (Q3 2022), and -$1.4 million (Q2 2022).